Table 1.

The results of phase 3 trials evaluating the efficacy of cetuximab to SCCHN

Trial	Patient setting	Treatment arm	OS Hazard ratio (95% CI)	p-value	Reference
IMCL-9815 (Bonner)	Locally advanced	BRT vs Radiation	0.74 (0.57–0.97)	0.03	[19]
RTOG 0522	Locally advanced	CRT with or without cetuximab	0.95 (0.74–1.21)	0.32	[24]
GORTEC 2007–01	Locally advanced	BRT with or without cisplatin	0.80 (0.61–1.05)	0.13	[25]
GORTEC 2007–02	Locally advanced	BRT with induction chemotherapy vs CRT	1.12 (0.86–1.46)	0.39	[23]
EXTREME	Recurrent/metastatic	Chemotherapy with or without cetuximab	0.80 (0.64–0.99)	0.04	[20]

*BRT: cetuximab with radiation. CRT: platinum-based chemotherapy with radiation